FMP
Day One Biopharmaceuticals, Inc.
DAWN
NASDAQ
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
7.74 USD
-0.16 (-2.07%)
Historical Prices
From:
To:
We are unable to load the chart at this time.
About
ceo
Dr. Jeremy Bender M.B.A., Ph.D.
sector
Healthcare
industry
Biotechnology
website
https://dayonebio.comexchange
NASDAQ
Description
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
CIK
0001845337
ISIN
US23954D1090
CUSIP
23954D109
Address
395 Oyster Point Boulevard
Phone
650 484 0899
Country
US
Employee
181
IPO Date
May 27, 2021
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
DAWN Financial Summary
CIK
0001845337
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
23954D109
ISIN
US23954D1090
Country
US
Price
7.74
Beta
-1.25
Volume Avg.
1.18M
Market Cap
784.48M
Shares
-
52-Week
6.41-18.07
DCF
30.12
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-7.59
P/B
-
Website
https://dayonebio.com
Upgrades and Downgrades
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest DAWN News
It looks like there's no news available.
